Dyer, Garofalo, Mann & Schultz L.P.A.
1-800-223-8897
Free Consultation24 Hours a Day
Se Habla Español
View Blog Navigation

Email Us Now For A Free Case Evaluation

Bold labels are required.

Please note that First AND/OR Last Name, and Email AND/OR Phone are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy

The Average Yaz/Yasmin Lawsuit Settlement Is $212,000

The victims of Yaz/Yasmin have collectively recovered $402.6 million in lawsuit settlements to date, but the drug's manufacturer, Bayer AG, expects that number to continue to skyrocket. The drug manufacturer is shelling out millions in settlements because of undisclosed side effects caused by birth-control drugs Yaz and Yasmin.

Medical studies have suggested that contraceptives containing drospirenone, such as Yaz/Yasmin, may triple the risk for potentially fatal blood clots. The data is convincing, as evidenced by the U.S. Food and Drug Administration's (FDA) recent mandate for Bayer to include blood clot warnings on the labels of Yaz and Yasmin. However, these warnings came too late for many women, who have already suffered blood clots while taking the drugs.

Many of these victims - or their surviving families - have sought legal recourse in product liability lawsuits. Of the product liability and wrongful death lawsuits that Bayer has settled so far, the average payout is $212,000.

If you or a loved one has been seriously harmed by Yaz/Yasmin, contact a skilled Ohio dangerous drugs attorney to explore your options and preserve your legal right to a claim.

Source: Bloomberg Businessweek, "Bayer's Yasmin Lawsuit Settlements Rise To $402.6 Million," Jef Feeley, July 31, 2012

No Comments

Leave a comment
Comment Information
FindLaw Network

Privacy Policy | Business Development Solutions by FindLaw, a Thomson Reuters business.